<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113150</url>
  </required_header>
  <id_info>
    <org_study_id>TurkiyeYIH</org_study_id>
    <secondary_id>Zaslidem</secondary_id>
    <nct_id>NCT02113150</nct_id>
  </id_info>
  <brief_title>A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery</brief_title>
  <official_title>A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turkiye Yuksek Ihtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turkiye Yuksek Ihtisas Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, randomized, clinical trial, we have investigated the effects of
      ketamine-based and remifentanil-based anesthetic protocol on perioperative serum cystatin-c
      levels, and creatinine and/or cystatin-c based eGFR equations in terms of acute kidney injury
      in CABG surgery.This study was approved by the Ethics Committee of Hospital and all patients
      were informed and gave written consent. Patients scheduled for elective CABG with
      cardiopulmonary bypass. Patients were randomly allocated to anesthesia with
      remifentanil-propofol-midazolam (RPM) group or ketamine-propofol-midazolam (KPM) group. Blood
      samples were obtained before induction of anesthesia (baseline), at the end of the operation,
      and postoperative days 1, 2, and 4.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>creatinin, BUN</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cystatin-c level</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>GFR value</measure>
    <time_frame>2 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>remifentanil, short acting opioid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketamine, intravenous anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>renal function</description>
    <arm_group_label>ketamine</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>renal function</description>
    <arm_group_label>remifentanil</arm_group_label>
    <other_name>ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients undergoing elective CABG with cardiopulmonary bypass

        Exclusion Criteria:

        patients undergoing emergency operation, combined operation, off-pump surgery, repeat
        surgery or valve surgery, patients presenting with chronic kidney disease or renal
        impairment, patients younger than 18 years old and neurological and/or psychiatric
        disturbances.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asl覺 Demir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkey Yuksek Ihtisas Education and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asl覺 Demir</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turkey Yuksek Ihtisas Education and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06550</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.tyih.gov.tr</url>
    <description>TYIH ETHICS COMMITTEE</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turkiye Yuksek Ihtisas Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>asl覺 demir</investigator_full_name>
    <investigator_title>Z.Asl覺 Demir, MD, Assoc.Prof</investigator_title>
  </responsible_party>
  <keyword>troponin t,cystatin-c,ketamine,remifentanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Cystatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

